{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:55:06Z","timestamp":1787320506314,"version":"build-2736575974"},"reference-count":29,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018688","name":"Korea Disease Control and Prevention Agency","doi-asserted-by":"publisher","award":["6600-6634-329"],"award-info":[{"award-number":["6600-6634-329"]}],"id":[{"id":"10.13039\/100018688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Chikungunya fever is a mosquito-borne infectious disease caused by the chikungunya virus (CHIKV). Recently, CHIKV has spread rapidly worldwide, raising global concerns. However, there is only one approved vaccine is available to prevent CHIKV infection; therefore, different platform vaccines development is a public health priority. The CHIKV genome encodes four non-structural polyproteins (nsP1-4) and one structural polyprotein (capsid, envelope 3, envelope 2, 6 K, and envelope 1). Previous studies have shown that N-linked glycans in viral proteins play important roles in regulating immune responses. Accordingly, in this study, we designed four CHIKV DNA vaccine candidates with mutated N-glycosylation sites in the full-length E and E I\/II proteins. Our results indicated that immunization of mice with the vaccine elevated the cytokines levels, including IFN-\u03b3, associated with T cell immune response. Furthermore, the truncated E protein with a deleted E III domain (E I\/II) exhibited better immunogenicity than the full-length E protein, and N-linked glycosylation of E I\/II protein induced a higher cell-mediated immune response. Overall, our study demonstrates that N-linked glycosylation of the E I\/II proteins of CHIKV significantly enhances cell-mediated immune responses, laying the foundation for the development of potential vaccination strategies against CHIKV.<\/jats:p>","DOI":"10.3390\/vaccines12101097","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T04:05:46Z","timestamp":1727323546000},"page":"1097","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunogenicity Analysis of Chikungunya Virus DNA Vaccine Based on Mutated Putative N-Linked Glycosylation Sites of the Envelope Protein"],"prefix":"10.3390","volume":"12","author":[{"given":"Kwangwook","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Vaccine Development Coordination, Center for Vaccine Research National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si 28159, Chungcheongbuk-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo Young","family":"Moon","sequence":"additional","affiliation":[{"name":"Division of Vaccine Development Coordination, Center for Vaccine Research National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si 28159, Chungcheongbuk-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungyeon","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Vaccine Development Coordination, Center for Vaccine Research National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si 28159, Chungcheongbuk-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Ohk","family":"Ouh","sequence":"additional","affiliation":[{"name":"Division of Vaccine Development Coordination, Center for Vaccine Research National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si 28159, Chungcheongbuk-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yookyoung","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Vaccine Development Coordination, Center for Vaccine Research National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si 28159, Chungcheongbuk-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3546-9477","authenticated-orcid":false,"given":"Heeji","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Vaccine Development Coordination, Center for Vaccine Research National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si 28159, Chungcheongbuk-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/0035-9203(55)90080-8","article-title":"An epidemic of virus disease in Southern Province, Tanganyika territory, in 1952\u20131953","volume":"49","author":"Robinson","year":"1955","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Schuffenecker, I., Iteman, I., Michault, A., Murri, S., Frangeul, L., Vaney, M.-C., Lavenir, R., Pardigon, N., Reynes, J.-M., and Pettinelli, F. (2006). Genome Microevolution of Chikungunya Viruses Causing the Indian Ocean Outbreak. PLOS Med., 3.","DOI":"10.1371\/journal.pmed.0030263"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI84417","article-title":"Chikungunya virus: Epidemiology, replication, disease mechanisms, and prospective intervention strategies","volume":"127","author":"Silva","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(14)60185-9","article-title":"Chikungunya in the Americas","volume":"383","author":"Nougairede","year":"2014","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S1473-3099(16)30385-1","article-title":"Chikungunya virus: An update on the biology and pathogenesis of this emerging pathogen","volume":"17","author":"Burt","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Dupuis-Maguiraga, L., Noret, M., Brun, S., Le Grand, R., Gras, G., and Roques, P. (2012). Chikungunya disease: Infection-associated markers from the acute to the chronic phase of arbo-virus-induced arthralgia. PLoS Neglected Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001446"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e1700020","DOI":"10.1002\/prca.201700020","article-title":"Ubiquitin-Conjugating Enzyme E2 L3 is Downregulated by the Chikungunya Virus nsP2 Protease","volume":"12","author":"Ramphan","year":"2018","journal-title":"Proteom.\u2014Clin. Appl."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.virol.2009.07.024","article-title":"Replication cycle of chikungunya: A re-emerging arbovirus","volume":"393","author":"Solignat","year":"2009","journal-title":"Virology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMra1406035","article-title":"Chikungunya Virus and the Global Spread of a Mosquito-Borne Disease","volume":"372","author":"Weaver","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7680","DOI":"10.1128\/JVI.00814-13","article-title":"Cross-Inhibition of Chikungunya Virus Fusion and Infection by Alphavirus E1 Domain III Proteins","volume":"87","author":"Nanda","year":"2013","journal-title":"J. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1128\/JVI.02792-15","article-title":"Dissecting the role of E2 protein domains in alphavirus pathogenicity","volume":"90","author":"Aliota","year":"2016","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e00435","DOI":"10.7554\/eLife.00435","article-title":"Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization","volume":"2","author":"Sun","year":"2013","journal-title":"eLife"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nature09555","article-title":"Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography","volume":"468","author":"Voss","year":"2010","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/j.bbamcr.2013.04.001","article-title":"N-linked protein glycosylation in the ER","volume":"1833","author":"Aebi","year":"2013","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Cell Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Stanley, P. (2011). Golgi glycosylation. Cold Spring Harb. Perspect. Biol., 3.","DOI":"10.1101\/cshperspect.a005199"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tim.2007.03.003","article-title":"Virus glycosylation: Role in virulence and immune interactions","volume":"15","author":"Vigerust","year":"2007","journal-title":"Trends Microbiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1128\/JVI.02427-08","article-title":"Role of N-Linked Glycosylation for Sindbis Virus Infection and Replication in Vertebrate and Invertebrate Systems","volume":"83","author":"Knight","year":"2009","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1038\/s41467-018-07704-x","article-title":"Implication for alphavirus host-cell entry and assembly indicated by a 3.5A resolution cryo-EM structure","volume":"9","author":"Chen","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1038\/s41467-021-23400-9","article-title":"Cryo-EM structure of the mature and infective Mayaro virus at 4.4 A resolution reveals features of arthritogenic alphaviruses","volume":"12","author":"Coimbra","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.vaccine.2007.10.046","article-title":"Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination","volume":"26","author":"Cohen","year":"2007","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41541-023-00722-x","article-title":"Strategic considerations on developing a CHIKV vaccine and ensuring equitable access for countries in need","volume":"8","author":"Cherian","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2301573","DOI":"10.1080\/21505594.2023.2301573","article-title":"Ixchiq (VLA1553): The first FDA-approved vaccine to prevent disease caused by Chikungunya virus infection","volume":"15","author":"Ly","year":"2024","journal-title":"Virulence"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(23)00641-4","article-title":"Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: A double-blind, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"401","author":"Schneider","year":"2023","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.bbagen.2019.05.012","article-title":"Exploitation of glycosylation in enveloped virus pathobiology","volume":"1863","author":"Watanabe","year":"2019","journal-title":"Biochim. et Biophys. Acta (BBA)-Gen. Subj."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"eabm0899","DOI":"10.1126\/scitranslmed.abm0899","article-title":"Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models","volume":"14","author":"Huang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/immuno1040032","article-title":"Immunological Mechanisms of Vaccine-Induced Protection against SARS-CoV-2 in Humans","volume":"1","author":"Goyal","year":"2021","journal-title":"Immuno"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1128\/JVI.02098-06","article-title":"Influences of Glycosylation on Antigenicity, Immunogenicity, and Protective Efficacy of Ebola Virus GP DNA Vaccines","volume":"81","author":"Dowling","year":"2007","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1743-422X-8-138","article-title":"Mutation of putative N-Linked Glycosylation Sites in Japanese encephalitis Virus Premembrane and Envelope proteins enhances humoral immunity in BALB\/C mice after DNA vaccination","volume":"8","author":"Zhang","year":"2011","journal-title":"Virol. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"102348","DOI":"10.1016\/j.sbi.2022.102348","article-title":"Glycosylation as a key parameter in the design of nucleic acid vaccines","volume":"73","author":"Ozdilek","year":"2022","journal-title":"Curr. Opin. Struct. Biol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/10\/1097\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:03:29Z","timestamp":1760112209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/10\/1097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["vaccines12101097"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12101097","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]}}}